First Quarter Fiscal 2010 Financial Results Conference Call
on November 2, 2009
Presentation at Oppenheimer's 20th Annual Healthcare Conference
on November 4, 2009
SAN MATEO, Calif., Oct. 19, 2009 (GLOBE NEWSWIRE) -- BioForm Medical, Inc. (Nasdaq:BFRM) announced that on Monday, November 2, 2009, it will report its financial results for the quarter ended September 30, 2009, which is its first quarter fiscal year 2010. The Company will issue the earnings press release before the NASDAQ Global Market opens and will hold a conference call with investors at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time).
BioForm Medical Chief Executive Officer Steve Basta will discuss the Company's results for the quarter ended September 30, 2009. The conference call may be accessed by dialing 800-309-1301 for callers in the U.S. and 719-457-2619 for international callers. Please notify the operator that you would like to join "BioForm Medical's First Quarter FY 2010 Earnings Call" and provide the participant code "9655432", if prompted.
BioForm Medical Chief Executive Officer Steve Basta is scheduled to provide a corporate overview of the Company at the Oppenheimer 20th Annual Healthcare Conference in New York City on Wednesday, November 4th, 2009, from 2:45 to 3:15 p.m. Eastern Time.
The financial results conference call and presentation at the upcoming investor conference will be webcast live on the Investor Relations section of BioForm Medical's website at http://investor.bioform.com/events.cfm. The online archive of the conference call and the presentation will be available approximately 90 minutes after the event and will continue to be available for approximately four weeks.
About BioForm Medical, Inc.:
BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California, developing products that enhance aesthetic procedures performed in dermatology and plastic surgery practices. BioForm Medical's lead product is Radiesse(R) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts.